Back to news

Vesicor Therapeutics and Black Hawk Acquisition Corporation Announce Closing of Business Combination

Globe Newswire•20/11/2026•08:00 ET
0

Key Highlights

  • ➤Business combination closed November 19, 2026, creating Vesicor Therapeutics Holdings
  • ➤VESI trading expected November 23, 2026, replacing Black Hawk’s BKHA listing
  • ➤Vesicor preparing IND-enabling studies for sole candidate ecm-RV/p53
  • ➤Vesicor says additional capital is needed, with no preclinical studies started

Expert Statements

Warren Hosseinion, Sr., MD, Chairman of the Board, Vesicor Therapeutics Holdings

“Closing this transaction gives Vesicor access to the public markets at the point where the Company needs it most, as we prepare to begin IND-enabling studies for ecm-RV/p53”

Luo Feng, PhD, Founder, Director and Chief Scientific Officer, Vesicor Therapeutics Holdings

“I founded Vesicor in 2008 with the goal of developing p53-based cancer therapeutics using precision-engineered microvesicles”

Luo Feng, PhD, Founder, Director and Chief Scientific Officer, Vesicor Therapeutics Holdings

“ecm-RV/p53 reflects many years of research, and we are focused on building on that foundation as we seek to advance the program toward clinical evaluation.”

Michael Tolentino, MD, Chief Executive Officer, Vesicor Therapeutics Holdings

“Our priority as a public company is clear: advance ecm-RV/p53 through IND-enabling studies and toward an IND submission to the FDA”

Michael Tolentino, MD, Chief Executive Officer, Vesicor Therapeutics Holdings

“We have a defined goal, an experienced team and a board that has the skills to advance the priorities of the Company. We look forward to reporting our progress to shareholders.”

SAN GABRIEL, Calif., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Vesicor Therapeutics Holdings, Inc. (“Vesicor” or the “Company”), an early development stage biotechnology company focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles, today announced the closing of its previously announced business combination with Black Hawk Acquisition Corporation (Nasdaq: BKHA) (“Black Hawk”). The transaction was approved by Black Hawk’s shareholders at an extraordinary general meeting held on October 13, 2026 and closed on November 19, 2026. In connection with the closing, Black Hawk domesticated from the Cayman Islands to Delaware and changed its name to Vesicor Therapeutics Holdings, Inc. The Company’s common stock is expected to begin trading on the Nasdaq Capital Market under the ticker symbol “VESI” on November 23, 2026.

Vesicor will be led by Michael Tolentino, MD, Chief Executive Officer; Luo Feng, PhD, Founder, Director and Chief Scientific Officer; Mitch Creem, MHA, Chief Financial Officer; and Warren Hosseinion, Jr., Chief Operating Officer. The Company’s Board of Directors consists of Warren Hosseinion, Sr., MD (Chairman), Luo Feng, PhD, Oded Levy, Frederick Woodruff Field and Qi Ouyang.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in